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Abstract: 
Binding of immunoglobulins and complement fragments to targets of adaptive immune 
responses can be monitored using collections of arrayed antigens and are used to generate 
profiles of antibody binding and function. The collection of reliable data on these 
reactions on a large scale requires the establishment of criteria from sample collection 
through reaction conditions to normalization strategies. 
We characterized the detection of IgG, complement C3 and C4 under conditions that 
closely imitate in vivo events and are also relevant for in vitro diagnostic purposes. 
Immune complex formation was modeled using nitrocellulose-based protein arrays and 
the effects of factors like anticoagulant use, serum dilution, time and bivalent cation 
concentrations were assessed. Blood samples from healthy controls (n=24) and patients 
with systemic autoimmune disease (n=60) were collected and correlations between 
classical laboratory tests and chip-based reference proteins were evaluated to optimize 
normalization schemes. 
Best signal-to-noise ratio and acceptable masking of IgG by complement C3 fragments 
was achieved at modest, five to ten-fold serum dilutions. C3 binding to captured human 
IgG was found to correlate best with serum C3 concentrations and C3 activity and is 
therefore an ideal reference feature for normalization of biological and methodological 
variations in complement activity and detection. 
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1. Introduction 
Immunoglobulins and complement proteins together constitute the second most abundant 
protein group of the plasma proteome. The complement system is a fundamental element 
of humoral immunity that constitutes the first protection line against pathogens. It 
comprises more than 30 proteins, some of which form an orchestrated enzyme cascade 
with multiple immunological effects. The cascade can be initiated by the classical, lectin 
or alternative pathways. These routes converge at the point of the cleavage of third 
complement component C3 which is followed by the common terminal pathway. Various 
structures initiate activation of the complement system, e.g. immune complexes (classical 
pathway); certain carbohydrates (lectin pathway); various microbes, aggregates of 
immunoglobulin (alternative pathway) (Walport, 2001). The final outcome of the 
activation depends on the presence of complement control proteins and the properties of 
initiator, like the isotype, avidity and glycosylation of antibodies in the immune complex 
(Arnold et al., 2006). Complement pathways can be directly activated by antigen bound 
antibodies and the efficiency of activation is not predictable undoubtedly knowing their 
isotypes and or subtypes (Daha et al., 2011), especially when enormous amount of 
antibody with different properties compete for the same antigen. Activation of the 
complement system initiates various biological events including cell lysis, inflammation, 
cell activation and opsonization; these versatile roles emphasize the need for the 
comprehensive understanding of complement function. Several tests have been developed 
for analyzing these diverse functions of complement (Mollnes et al., 2007). Most of these 
techniques measure the amount of complement components or test the three pathways for 
their intactness (Seelen et al., 2005) but are inappropriate for measuring antigen specific 
complement activation. 
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Immunoglobulins are the most diverse constituents of the plasma proteome. Arrayed 
antigens can be used to analyze a part of this diversity by generating binding patterns 
called antibody profiles (Prechl et al., 2010). Interaction between antigen and antibody 
results in the formation of immune complexes, which further interact with other serum 
components, such as complement, and cellular receptors. In order to generate a realistic 
picture about the events ensuing antigen recognition by antibody, we developed a protein 
microarray-based technique (Papp et al., 2007). On-chip complement activation generates 
functional antibody profiles and helps characterize immunity in a systematic way (Papp 
et al., 2008a; Papp et al., 2008b). Following  treatment of arrayed materials with slightly 
diluted serum, we can detect the amount of bound IgG and complement breakdown 
products, like C3b, iC3b, C3d, C4b and C4c fragments, in parallel. Since we did not 
attempt to determine the degree of fragmentation and also for the sake of simplicity from 
here on we refer to the various deposited fragments as C3 and C4. Here we report the 
modifying effect of different reaction conditions, like the type and concentration of blood 
sample, level of ions and the length of serum treatment, on IgG binding and complement 
activation in a planar microarray assay. Additionally we identify a normalization strategy 
that compensates for individual variations of complement activity. Applying suitable 
conditions during detection of antibodies on microarray, also their important effector 
function, their complement activating properties is measureable driving us closer to the 
understanding in vivo pathological processes.  
  
2. Materials and Methods: 
2.1 Materials: 
Properdin was purchased from CalBiochem and F(ab’)2 fragment of goat anti-human Ig γ 
chain specific antibody (anti-human IgG) from Jackson ImmunoResearch Laboratories. 
All other materials were purchased from Sigma-Aldrich. 
2.2 Blood collection: 
The study was approved by the national Scientific and Research Ethics Board; informed 
consent was obtained from each participant. Control serum samples were selected from 
the repository of the Drug Research Center. Patients with systemic lupus erythematosus 
(SLE) fulfilled the international criteria. Venous blood from some healthy volunteers was 
collected in different types of tubes: serum (BD Vacutainer, Plus Blood Collection Tube); 
EDTA-plasma (BD Vacutainer, K3E Tube, 0.084ml 15% K3E in 7ml tube); heparin-
plasma (Vacuette Greiner bio-one, lithium heparin containing tube); hirudin-plasma (50μl 
hirudin (50U) + 950μl blood); citrate-plasma (1ml 3.8% Na-citrate + 9ml blood). Plasma 
was centrifuged at 1000g for 10 minutes directly following blood collection; while for 
serum samples centrifugation was carried out 1 hour later, using the clotted blood. 
Supernatants (plasma/serum) were divided into aliquots and kept at -70°C until use. Only 
serum samples with available C3 concentration data and CH50 values, as determined by 
certified  clinical laboratories, were included in this analysis. 
2.3 Microarray production and measurement 
Experiments were carried out on nitrocellulose coated 16 pad FAST Slides (GE 
Healthcare) for the comparison of different reaction conditions and on 2 pad slides for 
serum profiling. Anti-human IgG, human IgG, properdin, pG and BSA were spotted in 
triplicates of 1/5 serial dilution (low, medium and high concentration) by BioOdyssey 
Calligrapher MiniArrayer (Bio-Rad). The starting concentration was usually 0.5mg/ml 
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except anti-human IgG and BSA that were used in 1mg/ml. Ready slides were kept in 
sealed non-transparent bags at 4°C.  
The basic protocol - that was modified sometimes, as described in the result section - is 
the following: dried arrays were rehydrated in PBS (4x5min) before using, then sub-
arrays were incubated in 70μl diluted or undiluted sample at 37°C for 1h, providing 
suitable conditions for complement activation. Sample dilution was carried out usually in 
Ca-Mg-VBS (2.5mM Ca
2+
, 0.7mM Mg
2+
, 0.05% Tween 20, 5% BSA, Veronal buffered 
saline) or when the complement blocking was the goal, ions were replaced with 25mM 
EDTA. Plasma/serum treated slides were washed in 0.05% Tween containing PBS, then 
incubated at room temperature for 30 minutes with fluorescently labeled detecting 
antibodies that were diluted in blocking buffer (0.05% Tween 20, 5% BSA, 0.05% azide, 
PBS). As mentioned in the results section, differently diluted, various antibodies were 
used for detection: goat F(ab’)2 fragment to human C3 antibody (Cappel, MP 
Biomedicals) labeled with Alexa 647 dye by us (5000x); ; FITC labeled goat anti-human 
C4 antibody (Cappel, MP Biomedicals) (2500x); biotinilated F(ab’)2 fragment of goat 
anti-human IgG γ chain specific antibody (Southern Biotechnologies) (5000x); PE-Cy5.5 
conjugated Streptavidin (eBioscience) (4000x). Antibodies that were used only in 
experiment that tests the effect of serum dilution: mixture of rabbit anti-human C3d + 
C3c-FITC (Dako) (2500x); allophycocyanin-conjugated F(ab’)2 fragment of goat anti-
human IgG γ chain specific antibody (Jackson ImmunoResearch Laboratories) (2500x). 
Then chips were washed again and following drying, slides were scanned on Typhoon 
Trio+ imager (Amersham Biosciences). 
The serum profiling data discussed in this publication have been deposited in the 
National Center for Biotechnology Information’s Gene Expression Omnibus (GEO) 
(Edgar et al., 2002) and are accessible through GEO series accession no. GSE26768 
(www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc). 
2.4 Analysis of microarray data 
Images of slides were analyzed with GenePix Pro 6.0 (Molecular Devices, Corp.) 
software after visual inspection. Relative intensity of fluorescence (RFI= FI median 
(pixels of spot) –FI median (pixels of local background)) was calculated for each spot, 
then the mean of the replicates were used for further analysis. Signal intensities were 
calculated by subtracting background from medians of three parallel signal intensities in a 
spreadsheet program (Microsoft Excel). Signals not exceeding two standard deviations of 
local background signals on a slide were clamped to an arbitrary value. 
 
3. Results 
3.1 Effect of anticoagulants on complement measurement 
Anticoagulants not only block blood clotting but some of them alter the efficiency of 
complement activation, as well. We tested the modifying effect of different blood 
collection methods on on-chip complement detection. Three probes with different 
obligate complement activating properties were printed on arrays: F(ab’)2 fragment of 
anti-human IgG, human IgG and properdin. Plasma containing generally used 
anticoagulants (EDTA, citrate, heparin, hirudin) was compared with serum, regarding 
their applicability for array-based complement measurement. Of note, during array 
treatment the thawed hirudin plasma formed a loose gel on the array surface, even though 
a recommended, published (Manderson et al., 2001) hirudin concentration was used. The 
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amount of bound C3 and C4 fragments was assessed following treatment of printed 
probes with undiluted and 5-fold diluted plasma/serum. The highest amount of C3 
fragment was detected in heparin plasma, while the lowest in EDTA containing plasma 
(Figure 1A). Depending on the probes, the amount of deposited C4 fragments in 
undiluted plasma/serum was high when citrate and also substantial where EDTA or 
heparin was used as anticoagulant, but in the case of hirudin plasma and serum, C4 signal 
was low (Figure 1B). C4 deposition is not expected on properdin spot because it is an 
alternative pathway initiator. When blood samples were diluted 5-fold in a buffer 
containing Ca
2+
 and Mg
2+
 ions, both C3 and C4 signals increased and differences 
between the blood collecting methods nearly disappeared. 
3.2 Correlation between serum dilution and complement activation measurement 
As it was shown above, dilution of samples increased the signal-noise ratio. In the next 
step, the effect of serum dilution on antibody and C3 detection was determined. Arrays 
were incubated in serially diluted serum for 1 hour and the bound IgG and C3 fragments 
were detected. Images of the slides on Figure 2A show that the higher the dilution the 
lower the background was. Above 10-fold dilution the C3 signal decreased on all three 
complement activators (Figure 2B). In contrast, the IgG signal increased with dilution. 
That complement activation had a negative impact on IgG detection best showed up on 
the printed human IgG spots which gave higher IgG signal when the array was incubated 
with buffer, instead of diluted serum. Anti-properdin antibodies are normally not present 
in serum explaining the lack of IgG signals on properdin spots. 
3.3 Dependence of complement activation on ion concentration  
Complement activity requires calcium and magnesium ions. Ca
2+
 ions take part in the 
recognition and activation phase of classical and lectin pathways and are critical for the 
stabilization of C1 and mannose binding lectin complexes (Thielens et al., 2001; 
Roumenina et al., 2005). Mg
2+
 ions facilitate factor B binding to C3(H2O) or C3b, and so 
contribute to the proper working of the alternative pathway. The physiological 
concentrations of Ca
2+
 and Mg
2+
 ions are 2.5mM and 0.7mM, respectively (WACKER et 
al., 1965). We tested the effect of five-times lower and higher ion concentrations on 
complement activation and IgG detection. Figure 3 shows that deposition of C3 
fragments on printed antibodies diminished when 5-times higher than physiological Ca
2+
 
ions were present in the solution. This effect of Ca
2+
 was not observed with properdin-
induced activation. On anti-human IgG and human IgG spots Mg
2+
 ion concentration was 
positively and negatively related with C3 and C4 fragment deposition, respectively. The 
IgG signals changed inversely with C3 signals. On properdin spots neither C4 nor IgG 
signal was detected. 
3.4 Kinetics of C3 and C4 fragment deposition  
The changes of C3 and C4 signals were measured for different lengths of incubation time 
using the serum of four healthy volunteers. The shapes of the curves were similar for the 
different serum samples (Figure 4). On the properdin and anti-human IgG spots the C3 
signal kept increasing in time, while detectable C4 signal reached its plateau on anti-
human IgG spot already in 10 minutes. On printed human IgG spots C3 levels reached a 
close to maximum value in about 10 minutes after a very fast initial increase, the C4 
signal reached its peak in 5 minutes, and started decreasing for the next 50 minutes.  
3.5 Correlation between total hemolytic activity, C3 concentrations and C3 deposition 
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Complement C3 concentrations and hemolytic activity vary between individuals on a 
relatively wide scale. This is coupled with variations introduced by sample collection, 
reaction conditions and signal detection steps. To compensate for these effects and in 
order to generate antigen specific complement C3 deposition profile that reflect immune 
responses rather than complement function, datasets need to be normalized. An ideal 
reaction for this purpose comprises antibody initiated complement activation, 
independent of serum antibody concentrations, reflects complement C3 concentrations 
and activity in a wide range. The complement activating agents characterized above were 
tested in this respect by correlating C3 deposition values with serum total C3 that was 
measured by a sandwich antibody pair on the array or by nephelometry in a certified 
laboratory. Correlation with total hemolytic activity CH50 was also addressed (Figure 5). 
We used sera from patients with systemic autoimmune disease and matched control 
subjects to obtain complement activity variations relevant for diagnostic applications 
(GEO ID: GSE26768). We found that anti-human IgG capture showed consistent positive 
correlation with total serum C3 and also with hemolytic activity. Printed human IgG 
showed correlation with chip-based C3 concentrations only. Unexpectedly, properdin-
induced complement activation showed no or negative correlation with C3 content or 
activity, due to the segregation of patients with systemic autoimmune disease from 
controls (Figure 5.). 
 
 4. Discussion: 
Contact between antigen and blood results in the binding of various recognition 
molecules to the antigen. Immersing microarrayed antigens in blood results in the 
generation of binding profiles of these recognition molecules, of which immunoglobulins 
are most important. It is also possible to follow events triggered by Ig binding, such as 
complement activation. Parallel measurement of these two reactions provides a functional 
map of the “immunome”. On-chip complement activation is suitable for the parallel 
measurement of bound antibody and antigen specific complement activation (Papp et al., 
2007). Importantly, reproducible and comparable measurement of complement activation 
requires controlled sample collection, storage, application and normalization conditions. 
Anticoagulants can interfere with complement function, depending on their mode of 
action. We compared various blood collection methods for determining their adaptability 
to the protein array technique. EDTA and citrate block blood coagulation by chelating 
Ca
2+
 and Mg
2+
 ions, which are important for complement activation. Hirudin is a 
thrombin specific inhibitor that does not interfere with complement (Chang, 1983; 
Mollnes et al., 2002); the anticoagulant effect of heparin is based on its binding to 
antitrombin III. The influence of heparin on the complement system is very complex; it 
has major effect on the alternative pathway but it also interferes with the classical 
pathway (Weiler and Linhardt, 1989; Weiler et al., 1992). The effect of heparin on 
complement activation is unusual because it inhibits complement activation at high 
concentration, whereas enhances the activation at low concentration (Mollnes et al., 
2002). When using undiluted plasma/serum, anticoagulants strongly influenced both C3 
and C4 fragment deposition (Figure 1). Compared to hirudin, an anticoagulant with no 
effects on complement, sodium citrate, EDTA and heparin inhibited or enhanced 
complement deposition. These effects were too complex to be explained by simple 
interactions and clearly indicated that undiluted plasma containing different 
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anticoagulants is not suitable for analysis. Fivefold dilution of the plasma samples in a 
buffer that contained Ca
2+
 and Mg
2+
 ions blunted anticoagulant effects, partly by 
restoring ions and partly by diluting the agents themselves. Thus, in addition to serum, 
which is the preferred substrate for testing, hirudinated plasma is also acceptable, while 
other anticoagulants should be avoided for on-chip complement tests.   
Unexpectedly, modest C4 signal was also observed on the alternative pathway activator 
properdin spots in the presence of heparin. This was probably the result of antibodies 
binding to properdin under these conditions (data not shown).  
As fivefold dilution of the samples in a buffer containing Ca
2+
 and Mg
2+
 ions had 
dramatic effect on the results, in the next step we tested the dependence of complement 
deposition and Ig detection on the extent of serum dilution. A relatively strong 
background C3 deposition was observed in undiluted serum that decreased gradually with 
dilution (Figure 2A). This background is probably the result of the continuous alternative 
pathway tick-over that gives rise to reactive C3 fragments, which bind to the surface. 
Best signal-to-noise ratio for C3 was achieved in the range of 5 to 10-fold serum dilution, 
confirming that efficient complement activity requires close-to normal concentrations of 
complement components. On the contrary, signals of both captured and printed IgG 
increased as a function of serum dilution (Figure 2B). In fact, original signal strength of 
the printed IgG was regained only when complement C3 deposition was negligible. 
These results suggest that deposited C3 fragments mask the bound antibodies and hinder 
detection at lower dilutions. Harboe et al. reported that hemolytic activity is lost at 16-
fold dilution by the alternative and at 1024-fold dilution by the classical pathway (Harboe 
et al., 2004). Our data is in agreement with those data. Spotted human IgG activates 
mainly the classical, while properdin mainly the alternative pathway. Printed goat anti-
human IgG F(ab’)2 fragments also directly activate the human alternative complement 
system (Reid, 1971); that effect decreases dramatically above the 10-fold dilution which 
explains the shape of the observed curve.  
We tested the effect of bivalent cation concentrations on the three printed test materials. 
Printed anti-human IgG and human IgG activate the classical pathway that needs Ca
2+
 
ions. As figure 3 shows, 5-fold increase in Ca
2+
 ion concentrations diminished C3 
fragment deposition. On these spots the binding of C3b fragments also initiated the 
alternative pathway and increasing amounts of Mg
2+
 ions modestly increased the C3 
signal. Excess of Mg
2+
 ions overdrives the positive feedback loop of the alternative 
pathway. Therefore the newly formed C3b fragments masked the bound C4 and IgG 
molecules lowering C4 and IgG signals. Even though the alternative pathway activated 
by properdin is Mg
2+
 ion-dependent, reducing Mg
2+
 concentrations to 20% of the 
physiological levels did not decrease the C3 signal substantially, except in the presence of 
elevated amounts of Ca
2+
. Healthy serum does not contain anti-properdin antibodies and 
lacks IgG and C4 signals on properdin.  
For determining the kinetics of complement fragment deposition, C3 and C4 was 
detected simultaneously at different points of time. C3 signals increased throughout the 
2-hour test in all three assays, though at different rates. On printed anti-human IgG spots 
the C4 signal reached its plateau at 10 minutes, while on printed human IgG spots, where 
classical pathway initiates complement activation, C4 signals increased for 5 minutes, 
then dropped back to a relatively constant level by 30 minutes. The classical pathway 
initiator C1q directly bound to printed human IgG antibodies, explaining the very fast C4 
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deposition. The C4 signal decrease that followed is explainable by C4 degradation and 
the masking effect of C3. Overall, complement deposition can be reliably measured 
starting from 30 minutes, and steady state changes further increase C3 signals for at least 
another 90 minutes. 
Based on these observations complement IgG binding and complement C3 and C4 
deposition was measured from 5-fold diluted sera, allowing 60 minutes in the presence of 
physiological cation concentrations for the reaction to take place. Systemic lupus 
erythematosus is an immune complex mediated disease that is often accompanied by 
decreased complement activity due to consumption. Complement C3 deposition in serum 
samples from patients with systemic autoimmune disease and control subjects showed 
similar correlations to total C3 levels and hemolytic activity as assessed by anti-human 
IgG capture. Notwithstanding, C3 deposition on properdin was rather independent of 
total C3 and C3 activity levels in patients with systemic lupus erythematosus. Capturing 
IgG from serum therefore seems to be suitable for normalizing biological and 
methodological variations when assaying C3 deposition on protein arrays. In addition to 
secondary antibodies, such as the goat anti-human IgG used in these assays, B-cell 
superantigens, e.g. protein G, perform similarly and are potential alternatives (data not 
shown). 
Trouw et al. presented an ELISA based technique for measurement of complement 
activation of antigen bound antibodies, treating antigen coated wells with EDTA 
containing patient serum then using a normal human serum as common complement 
source for all sample (Trouw et al., 2009). This approach also achievable with our 
microarray method, but based on our experiments, this setup increases the background 
and the variance of data. Various serum components from active complement containing 
normal human serum can modify the result, as their react with bound elements of serum 
samples derived from patient. We suggest applying the serum of patient as complement 
source as in this way we could gain information really the serum reactivity of the given 
individual. Using suitable control spots on the same array, differences in overall 
complement activation is removable, that approach would not be achievable in ELISA 
method.  
In conclusion, these results identify optimal conditions for the parallel measurement of 
IgG binding and complement activation on protein microarrays. The identified conditions 
- with limited serum dilution compared other techniques for antibody detection- enables 
even to the low affinity antibodies to compete for epitopes that better mimic the 
environment of antigen recognition in blood. With the utilization of IgG capture agents 
one can normalize C3 deposition values to obtain datasets that reflect complex 
interactions between antigen panels and the serum proteome. 
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Figure legends 
Figure 1.: Effect of anticoagulants on on-chip complement activation  
Proteins that initiate complement activation were printed on nitrocellulose as arrays. Goat 
anti-human IgG captures IgG from serum, while printed human IgG directly triggers 
classical pathway activation. Properdin stabilizes C3 convertase of the alternative 
pathway. The arrays were treated with plasma containing the indicated anticoagulants or 
serum, each undiluted or in a 1:5 dilution. The amounts of bound C3 (A) and C4 (B) 
fragments were detected using fluorescently labeled secondary antibodies. Blood samples 
with different anticogulants were collected at the same time from three different healthy 
donors and each experiment was performed twice. Relative fluorescence intensities (RFI) 
are shown. 
 
Figure 2.: Serum dilution influences protein detection 
For the comparison of reaction conditions, 16-pad arrays were incubated with serially 
diluted serum. FITC conjugated anti-human C3d+c and anti-human-IgG-APC antibodies 
were used for detection of bound IgG and C3 fragments, respectively. In a control sub-
array, only buffer was used for incubation. A) Representative image of a chip from four 
experiments and the layout of the sub-array. B) Average relative fluorescence intensities 
of the medium diluted printed probes are plotted as a function of serum dilution; SD 
values are indicated. BB refers to Bromophenol Blue containing spots those printed only 
for proper positioning. 
 
Figure 3.: Bivalent cations strictly control complement activity  
Protein arrays were incubated in five-fold diluted serum. Ca-Mg-VBS buffer was used 
for dilution (see Materials and Methods), with the ion concentrations adjusted to reach 
the final concentrations shown on the x and y axes. Graphs show C3, C4 and IgG RFI 
values of the three complement activating proteins. Data are representative of four 
independent experiments.  
 
Figure 4.: Kinetics of complement signals: 
Arrays were incubated for different periods of time shown in 5-fold diluted serum, 
derived from 4 healthy people. The control sub-array, indicated as 0 point, was incubated 
for 120 min in 25mM EDTA containing diluted serum to completely block complement 
activation. Anti-human C3-Alexa 647 and anti-human C4-FITC detecting antibodies 
were used for measuring bound C3 (black line, full symbol) and C4 (gray line, empty 
symbol) fragments on the three complement activators.  
 
Figure 5.: Correlation between on-chip complement C3 deposition on the obligate 
activators and total C3 concentration and activity  
C3 deposition was measured in sera from patients with autoimmune disease (Systemic 
lupus erythematosus, SLE) and control subjects using the complement activating 
substances described above. Serum complement C3 was estimated by an antibody pair on 
the array (anti-human C3) or by nephelometry in a clinical laboratory. Hemolytic activity 
(CH50 value) was measured by an in vitro diagnostic assay that detects soluble terminal 
pathway complex C5b-9. Correlations between C3 deposition values and C3 
concentration and hemolytic activity are shown.  
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Correlation coefficients and p values of Spearman rank correlations are indicated. 
 
 
Abbreviations:  
RFI, relative fluorescence intensity;  
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